Alector, Inc. — Q3 2023 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company focused on immuno-neurology. This filing covers the quarter and nine months ended September 30, 2023. Alector had no approved products and no product-sales revenue; collaboration agreements with GSK and AbbVie were its principal revenue source.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $9.1m | $14.9m | $81.9m | $119.2m |
| Research and development | $46.3m | $48.3m | $144.4m | $155.9m |
| General and administrative | $13.4m | $14.3m | $41.8m | $45.6m |
| Net loss | $44.5m | $46.1m | $89.0m | $80.9m |
| Net loss per share, diluted | $(0.53) | $(0.56) | $(1.07) | $(0.98) |
As of September 30, cash and cash equivalents were $102.0m and marketable securities were $486.9m, totaling $588.9m. Working capital was approximately $457.7m. Management expects existing cash, cash equivalents, and investments to fund operations and capital expenditures through 2025, subject to assumptions that could prove inaccurate. No borrowings are disclosed; lease liabilities were $40.2m in total. Gross margin is not presented, and is not a meaningful reported metric for this clinical-stage company.
Operating cash flow was $(138.1)m for the first nine months of 2023, versus $28.6m provided in the prior-year period. The change chiefly reflected lower deferred revenue and collaboration-partner refund liabilities; 2022 operating cash flow benefited from a $200m GSK payment. Investing activities provided $83.8m, primarily reflecting net maturities of marketable securities; financing activities provided $2.0m.
Material changes versus prior comparable periods
- Q3 revenue fell $5.7m year over year, primarily from lower AL101 collaboration revenue, including a $4.6m reduction related to higher expected costs for the AL101 Alzheimer’s program.
- Nine-month revenue declined $37.3m. The comparison was affected by $68.9m of revenue recognized in Q2 2022 following the AL003 program termination and other changes in estimated costs; 2023 increases for AL101 and AL002 partly offset the decline.
- Operating expenses declined in both comparison periods, reflecting program prioritization and, for the nine-month period, greater GSK cost-share reimbursements and lower manufacturing costs. Despite lower nine-month expenses, operating loss widened to $104.3m from $82.4m, as revenue fell substantially.
- Higher investment yields increased other income to $7.4m for Q3 and $18.9m for the first nine months, versus $2.3m and $4.0m, respectively, in 2022.
Outlook, management commentary, and risks
- Development focus is latozinemab for frontotemporal dementia (FTD) and AL002 and AL101 for Alzheimer’s disease. Management expects expenses to increase as programs advance, while noting the company may seek additional financing; a shelf registration permits issuance of up to $400m of securities.
- After quarter-end, Alector reported completion of INFRONT-3 enrollment in October 2023: 103 symptomatic and 16 at-risk participants, subject to revised-protocol approval in countries outside the United States. The pivotal latozinemab trial’s primary analysis is focused on symptomatic participants.
- INVOKE-2 enrollment for AL002 was completed in Q3; data were expected in Q4 2024. GSK commenced patient screening in Q4 2023 for an AL101 Phase 2 early Alzheimer’s trial.
- GSK amendments introduced Alector funding and cost sharing of up to $140.5m for the initial AL101 Alzheimer’s Phase 2 trial. Contract modifications also created collaboration-partner refund liabilities and reduced the GSK agreement’s transaction price; the filing reports a $570.4m transaction price at September 30, 2023.
- Alector reduced its workforce by approximately 11% (about 30 employees) in March 2023 to prioritize late-stage programs. It reported $1.7m of restructuring costs for the first nine months and expected no additional restructuring costs before year-end.
- Alector disclosed treatment-emergent MRI findings resembling ARIA in the AL002 INVOKE-2 trial. Most were asymptomatic and non-serious, but serious events occurred, including after dosing and enrollment of APOE e4/e4 participants had been discontinued. Earlier MRI monitoring and independent monitoring continue.
- Key risks include clinical-trial efficacy, safety and timing; patient enrollment; reliance on GSK, AbbVie and contract manufacturers; uncertain future financing; and the possibility that development costs or collaboration revenue estimates change. Management reported no litigation expected to have a material adverse effect and concluded disclosure controls were effective.
Important facts for investors to verify
- Progress, safety monitoring and regulatory alignment for INFRONT-3, including the status of protocol approvals outside the United States.
- AL002 trial safety and the expected timing and interpretation of Q4 2024 data; monitor the AL101 Phase 2 trial start and enrollment.
- Actual cash burn, collaboration receipts and cost-sharing obligations against management’s through-2025 runway estimate.
- Changes in expected program costs, deferred revenue and refund liabilities under the GSK and AbbVie agreements.
- Whether clinical, collaboration, financing or operating developments alter the company’s program priorities or funding needs.